Martin Shkreli probably won’t be attending the J.P. Morgan Healthcare conference in San Francisco this week, the premiere event for pharmaceutical firms to talk shop and cut deals. After all, it was just last month that he was escorted out of his New York apartment in handcuffs for alleged securities violations. But his presence looms large, even if some top drug executives can’t bring themselves to say his name out loud.
